SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2006 / Cilt: 6 - Sayı: 3

Current management of no-reflow

No-reflow'a güncel yaklaşım

Bilal BOZTOSUN
Yılmaz GÜNEŞ
Cevat KIRMA
Pages
255–260
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therapeutic approach to such a phenomenon requires knowledge of mechanisms, methods of diagnosis and response to treatment modalities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Restoration of epicardial blood flow is not necessarily associated with microvascular and tissue perfusion.
📊
Key Findings & Data:The mechanisms responsible for no-reflow are uncertain and prevailing mechanism operating in the individual patient may also differ.
💡
Conclusion & Impact:Therapeutic approach to such a phenomenon requires knowledge of mechanisms, methods of diagnosis and response to treatment modalities.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Restoration of epicardial blood flow is not necessarily associated with microvascular and tissue perfusion. The mechanisms responsible for no-reflow are uncertain and prevailing mechanism operating in the individual patient may also differ. Restoration of perfusion at the tissue level is expected to have beneficial effects on left ventricular function. Therapeutic approach to such a phenomenon requires knowledge of mechanisms, methods of diagnosis and response to treatment modalities.

Özet

Epikardiyal kan akımının sürdürülmesi her zaman mikrovasküler dolaşımı ve doku perfüzyonunu sağlamamaktadır. “No-reflow” adı verilen olaydan sorumlu mekanizmalar iyi bilinmemektedir. Ayrıca etki eden mekanizma hastalar arasında farklılık gösterebilmektedir. Doku perfüzyonun sağlanmasının sol ventrikül fonksiyonlarını olumlu yönde etkilediği bilinmektedir. Etkin tedavinin sağlanması için sorumlu mekanizmaların daha iyi bilinmesi gerekmektedir.

🔖

Cite This Article

BOZTOSUN, B., GÜNEŞ, Y., KIRMA, C. (2022). Current management of no-reflow. Anadolu Kardiyoloji Dergisi, Cilt: 6 - Sayı: 3, 255–260. https://ajindex.com/articles/437305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in dogs. J Clin Invest 1974; 54: 1496-508
  2. Safian RD. No-reflow. In: Safian RD, Freed M., editors. The Manual of Interventional Cardiology. 3rd ed. Royal Oak, Mich.: Physicians' Press; 2001. p.413-9
  3. Kondo M, Nakano A, Saito D, Shimono Y. Assessment of “microvascular no-reflow phenomenon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998; 32: 898-903
  4. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003; 89: 731-7
  5. L Galiuto. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenic classification. Heart 2004; 90: 123-5
  6. Reffelmann, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart 2002; 87: 162-8
  7. Popma JJ,Topol EJ, Hinohara T,Pinkerton CA, Baim DS,King 3rd SB, et al. Abrupt vessel closure after directional coronary atherectomy. The U.S. Directional Atherectomy Investigator Group. J Am Coll Cardiol 1992; 19: 1372 - 9
  8. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B,DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43: 276-83
  9. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994; 89: 1254-61
  10. Gailuto L, DeMaria AN, del Balzo U, May-Newman K,Flaim SF,Wolf PL et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin-a selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102: 3111-6. 11. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F et al. ST-segment resolution and infarct related artery patency and flow after thrombolytic therapy. Am J Cardiol 2000; 85: 299-304
  11. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994; 89: 2514-8
  12. Vallejo E, Pena-Duque MA, Norono O, Ban Hayashi E, Gaspar J, Villavicencio R et al. The no-ref